In his latest article for Pharmacy Times, Ned Milenkovich, chair of Much’s Health Care group, explored the Most Favored Nation (MFN) drug pricing initiative and what it could mean for both the pharmacy industry and its patients. He analyzes market dynamics and examines how efforts to align U.S. drug prices with those in other countries may lower costs for patients.
Article
Decoding Most Favored Nation: Expert Insights on the Impacts to Patients, Pharma, and InnovationPharmacy Times
9.12.2025
